Navigation Links
The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017
Date:10/8/2008

Extensive Need for Disease-Modifying Agents Creates Significant Opportunity for Drug Developers, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the anticipated approval of only one disease-modifying therapy over the next decade, the market for disease-modifying osteoarthritis drugs will experience exponential growth, increasing from $477 million in 2007 to nearly $3.8 billion in 2017.

The new Pharmacor report entitled Osteoarthritis: Disease-Modifying Therapies, finds that, following its anticipated approval in 2011, the uptake of Servier's Protelos, as well as off-label use of Novartis/Nordic Bioscience/Emisphere Technologies' SMC-021 for its disease-modifying potential, will drive the tremendous growth of the osteoarthritis drug market through 2017. Market growth will also be fueled by increasing prevalence of osteoarthritis and an increase in drug-treatment rates in the United States and Europe as patients switch from over-the-counter agents with unproven efficacy to new prescription drugs that promise to slow structural progression and improve symptoms of the disease. According to the report, there are 37 million patients diagnosed with osteoarthritis in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The report finds that, owing to the need for disease-modifying drugs, significant opportunity remains for developers of osteoarthritis drugs. Additionally, although some studies have suggested that glucosamine, chondroitin sulfate, diacerein and avocado soybean unsaponifiables may slow the structural progression of osteoarthritis, these agents are not widely accepted as disease-modifying therapies.

"Because of the controversy surrounding the efficacy of agents such as glucosamine or chondroitin sulfate, physicians' responses varied widely in regard to prescribing or recommending these agents to osteoarthritis patients," said Amy Whiting, Ph.D., analyst at Decision Resources. "Although some rheumatologists might recommend glucosamine or chondroitin sulfate to their patients, interviewed experts say that the benefit of these agents has never been proven."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed

decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.

Christopher Comfort Elizabeth Marshall

781-296-2597 781-296-2563

ccomfort@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
6. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... NEW ORLEANS, La. (PRWEB) , ... July 21, ... ... tool to allow 4th-year medical students improve their chances of acceptance to a ... particularly for those who have earned degrees outside the U.S. , According to ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... insight into why concussion rates are on the rise, say researchers presenting their ... today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: